Here is the design of a clinical trial:

Official Title: The Energy Conservation Education Intervention For People With End-stage Kidney Disease Receiving Haemodialysis (EVEREST)

Included conditions:
- Fatigue
- End Stage Kidney Disease
- Quality of Life

Study Armgroups:
- {'label': 'Intervention', 'type': 'EXPERIMENTAL', 'description': 'Participant of the cluster randomised to the intervention group will receive both the usual care from their healthcare providers and EVEREST delivered by the researcher who is a nurse.', 'interventionNames': ['Other: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis']}
- {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'Participants of the cluster randomised to the control group will receive usual care (standard care with no formalised, structured or tailored interventional to reduce symptom/s) from their healthcare providers'}

Interventions:
- {'type': 'OTHER', 'name': 'Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis', 'description': 'The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.', 'armGroupLabels': ['Intervention']}

Primary Outcomes:
- {'measure': 'Changes in Fatigue Symptom Inventory (FSI)', 'description': 'Fatigue Symptom Inventory (FSI) will be used to assess the severity, frequency, interference associated with fatigue and daily pattern of fatigue. The scale consists of 14 items rated on the 11-point items.', 'timeFrame': 'Baseline and week 4'}
- {'measure': 'Changes in Fatigue Symptom Inventory (FSI)', 'description': 'The scale consists of 14 items rated on the 11-point items.', 'timeFrame': 'Baseline and week 8'}
- {'measure': 'Changes in Fatigue Symptom Inventory (FSI)', 'description': 'The scale consists of 14 items rated on the 11-point items.', 'timeFrame': 'Baseline and week 12'}

Please estimate the sample size based on the assumption: 
80% power, significance level of 0.05, moderate intra-cluster coefficient of 0.03, 20% inflation for attrition, and 15% inflation for non-normality of data.
Sample size
        G power software was used to calculate the sample size by performing the priori power analysis for an independent group two-tailed t-test. The sample size was calculated based on a large effect size (Cohenâs d from 0.90 to 1.5) taken from a previous study in patients with breast cancer on management of fatigue (measured with fatigue symptom inventory (FSI)) with yoga intervention.39 To have resultant 80% power, an effect size of 0.8 and a significance of 0.05, 52 participants are needed (26 in each group). As this study uses a cluster design, and assuming a moderate intra-cluster coefficient of 0.03, the sample size is adjusted to compensate for design effect. To compensate for attrition and to avoid the possibility of non-normality of data, the calculation is further inflated by 20% and again 15%, respectively. After adjusting for these, a final sample size of 126 (63 in each group) is required.